These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 25446566)
1. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. Cazzola M; Calzetta L; Page CP; Rogliani P; Facciolo F; Gavaldà A; Matera MG Eur J Pharmacol; 2014 Dec; 745():135-43. PubMed ID: 25446566 [TBL] [Abstract][Full Text] [Related]
2. Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside. Cazzola M; Calzetta L; Ora J; Puxeddu E; Rogliani P; Matera MG Respir Med; 2015 Oct; 109(10):1305-11. PubMed ID: 26303336 [TBL] [Abstract][Full Text] [Related]
3. Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease. D'Urzo T; Donohue JF; Price D; Miravitlles M; Kerwin E Expert Rev Respir Med; 2015 Oct; 9(5):519-32. PubMed ID: 26366803 [TBL] [Abstract][Full Text] [Related]
4. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. Cazzola M; Rogliani P; Matera MG Expert Opin Pharmacother; 2013 Apr; 14(6):775-81. PubMed ID: 23472632 [TBL] [Abstract][Full Text] [Related]
5. Aclidinium bromide and formoterol fumarate for the maintenance treatment of chronic obstructive pulmonary disease. Haley R; Gupta N; Sethi S Expert Rev Clin Pharmacol; 2020 Feb; 13(2):103-113. PubMed ID: 31951778 [No Abstract] [Full Text] [Related]
6. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. Rogliani P; Calzetta L; Ora J; Lipsi R; Segreti A; Matera MG; Cazzola M Eur J Pharmacol; 2015 Aug; 761():383-90. PubMed ID: 25952728 [TBL] [Abstract][Full Text] [Related]
7. Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease. Babu KS; Morjaria JB Ther Adv Respir Dis; 2015 Apr; 9(2):56-68. PubMed ID: 25754881 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. Calzetta L; Rogliani P; Page C; Rinaldi B; Cazzola M; Matera MG Pulm Pharmacol Ther; 2019 Jun; 56():39-50. PubMed ID: 30876907 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. Cazzola M; Calzetta L; Puxeddu E; Ora J; Facciolo F; Rogliani P; Matera MG Respir Res; 2016 Jun; 17(1):70. PubMed ID: 27296533 [TBL] [Abstract][Full Text] [Related]
10. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo. Rogliani P; Matera MG; Facciolo F; Page C; Cazzola M; Calzetta L Br J Pharmacol; 2020 Mar; 177(5):1150-1163. PubMed ID: 31660611 [TBL] [Abstract][Full Text] [Related]
11. Interaction between corticosteroids and muscarinic antagonists in human airways. Cazzola M; Calzetta L; Rogliani P; Puxeddu E; Facciolo F; Matera MG Pulm Pharmacol Ther; 2016 Feb; 36():1-9. PubMed ID: 26656790 [TBL] [Abstract][Full Text] [Related]
12. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD. Donohue JF; Soong W; Wu X; Shrestha P; Lei A Respir Med; 2016 Jul; 116():41-8. PubMed ID: 27296819 [TBL] [Abstract][Full Text] [Related]
13. Symptom variability and control in COPD: Advantages of dual bronchodilation therapy. Di Marco F; Santus P; Scichilone N; Solidoro P; Contoli M; Braido F; Corsico AG Respir Med; 2017 Apr; 125():49-56. PubMed ID: 28340862 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi. Calzetta L; Rogliani P; Mattei M; Alfonsi P; Cito G; Pistocchini E; Cazzola M; Matera MG COPD; 2017 Oct; 14(5):526-532. PubMed ID: 28745522 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. Calzetta L; Matera MG; Cazzola M Eur J Pharmacol; 2015 Aug; 761():168-73. PubMed ID: 25981302 [TBL] [Abstract][Full Text] [Related]
16. Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base. D'Urzo AD; Singh D; Donohue JF; Chapman KR Ther Adv Respir Dis; 2019; 13():1753466619850725. PubMed ID: 31096854 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Calzetta L; Cazzola M; Page CP; Rogliani P; Facciolo F; Matera MG Pulm Pharmacol Ther; 2015 Jun; 32():15-23. PubMed ID: 25899618 [TBL] [Abstract][Full Text] [Related]
18. Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients? Blasi F; Canonica GW; Miravitlles M Respir Res; 2017 Jan; 18(1):19. PubMed ID: 28100244 [TBL] [Abstract][Full Text] [Related]
19. Aclidinium bromide combined with formoterol inhibits remodeling parameters in lung epithelial cells through cAMP. Lambers C; Costa L; Ying Q; Zhong J; Lardinois D; Dekan G; Schuller E; Roth M Pharmacol Res; 2015 Dec; 102():310-8. PubMed ID: 26546746 [TBL] [Abstract][Full Text] [Related]
20. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. Calzetta L; Page CP; Spina D; Cazzola M; Rogliani P; Facciolo F; Matera MG J Pharmacol Exp Ther; 2013 Sep; 346(3):414-23. PubMed ID: 23766543 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]